Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasser Ged

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Journal for Immunotherapy of Cancer|January 20, 2025
Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockadeStephanie L Alden, Soren Charmsaz, Howard L Li, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2022
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in OncologyRobert J Motzer, Eric Jonasch, Neeraj Agarwal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 23, 2024
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024Robert J Motzer, Eric Jonasch, Neeraj Agarwal, et al.
The Journal of Clinical Investigation|October 15, 2024
Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signaturesChester J Kao, Soren Charmsaz, Stephanie L Alden, et al.
The Journal of Clinical Investigation|March 17, 2025
Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signaturesChester J Kao, Soren Charmsaz, Stephanie L Alden, et al.
The Lancet. Oncology|June 28, 2024
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 studyMohamad E Allaf, Se-Eun Kim, Viraj Master, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Journal for Immunotherapy of Cancer|January 20, 2025
Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockadeStephanie L Alden, Soren Charmsaz, Howard L Li, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2022
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in OncologyRobert J Motzer, Eric Jonasch, Neeraj Agarwal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 23, 2024
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024Robert J Motzer, Eric Jonasch, Neeraj Agarwal, et al.
The Journal of Clinical Investigation|October 15, 2024
Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signaturesChester J Kao, Soren Charmsaz, Stephanie L Alden, et al.
The Journal of Clinical Investigation|March 17, 2025
Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signaturesChester J Kao, Soren Charmsaz, Stephanie L Alden, et al.
The Lancet. Oncology|June 28, 2024
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 studyMohamad E Allaf, Se-Eun Kim, Viraj Master, et al.
Pageof 6